Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026

INTEGRA LIFESCIENCES HOLDINGS CORP

Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.
Ratio steps down to 4.75:1 (Sep 2026), 4.50:1 (Dec 2026), and 4.00:1 (Mar 2027 onward).
No increase in total indebtedness; temporary restrictions on investments, liens, and restricted payments during Covenant Relief Period.
Amendment effective June 6, 2025, to Seventh Amended and Restated Credit Agreement dated March 24, 2023.
Company temporarily prohibited from using leverage 'step-up' for permitted acquisitions during Covenant Relief Period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.